Tag Archives: AI

RESI Europe 2026 Innovator’s Pitch Challenge Winners 

31 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At RESI Europe 2026 in Lisbon, more than 20 innovative companies participated in the Innovator’s Pitch Challenge (IPC), showcasing cutting-edge technologies across drugs, devices, diagnostics, and digital health. The IPC continues to serve as a powerful platform for early-stage life science companies to engage directly with active investors and strategic partners. 

Each finalist delivered a 6-minute pitch followed by a 7-minute live Q&A with a panel of investor judges, creating a dynamic and interactive evaluation process. Beyond the stage, participating companies also connected with attendees through dedicated poster presentations and 1:1 partnering meetings, maximizing visibility and investor engagement throughout the event. 

A defining feature of the IPC is the RESI cash voting system. Registered attendees, including investors, startup executives, and industry experts, allocated their RESI cash to the companies they found most compelling. Voting was based on pitch performance, Q&A responses, and direct interactions during partnering meetings and networking sessions. 

Life Science Nation is proud to announce the top three winners of the RESI Europe 2026 Innovator’s Pitch Challenge: 

1st Place 2nd Place 3rd Place
StimOxyGen Amets Biotechnology You2Yourself

These companies stood out for their strong scientific foundations, clear value propositions, and ability to engage investor interest. 

Applications are now open for upcoming Innovator’s Pitch Challenges. Companies can apply to pitch at RESI San Diego 2026 and take the stage in front of a global network of investors and partners. 

Apply to Pitch at RESI San Diego

Tags: , , , , , , , , , , , , ,

Best Practices for Cap Table Management: What Founders Need to Know Before Their Next Raise 

31 Mar

By Sougato Das, President and COO, LSN

Sougato-Das

Early-stage companies often focus heavily on product development, market traction, and investor outreach—but one of the most critical foundations of long-term success lies in how equity is structured from the very beginning. A well-managed cap table is not just an administrative tool; it is a strategic asset that can influence fundraising outcomes, talent acquisition, and overall company growth.

To help founders navigate this essential aspect of building a company, J.P. Morgan and Polsinelli are hosting an upcoming webinar, “Best Practices for Cap Table Management.” This practical, founder-focused session is designed to equip early-stage leaders with the knowledge needed to make informed equity decisions and avoid costly mistakes down the road.

Register for the Webinar

The session will cover key fundamentals every startup team should understand, beginning with how to approach founder equity splits. Establishing fair and strategic ownership early on can prevent misalignment and friction as the company scales. From there, the discussion will move into dilution—an inevitable part of fundraising—and how founders can plan for and manage it effectively.

Another critical topic is the use of SAFE notes, which have become increasingly common in early-stage financing. While they offer flexibility, they can also introduce complexity if not fully understood. This webinar will break down how SAFE notes work and how they impact future equity distribution.

Importantly, the session will also explore how cap table structure directly affects fundraising outcomes. Investors often scrutinize ownership distribution, and a poorly structured cap table can create hesitation or even derail a deal. In addition, speakers will highlight the importance of building a thoughtful stock option pool, an essential tool for attracting and retaining top talent in competitive markets.

This webinar is particularly relevant for founders, CEOs, and CFOs who are looking to strengthen their financial strategy, prepare for upcoming funding rounds, and build companies that scale responsibly.

The session will take place on April 14, 2026 at 11:00 AM ET and will feature insights from industry experts Vanessa Blanco (J.P. Morgan), Alan Gould (J.P. Morgan), Sara Dauber (J.P. Morgan), Jeremy Arak (Polsinelli), and Sougato Das (Life Science Nation).

Attendees should note that this webinar will not be recorded and will be available exclusively to live participants, making attendance especially valuable for those looking to gain actionable insights in real time.

Sign Up Webinar

Tags: , , , , , , , , , , , , , , , , , , ,

RESI Europe 2026 Program Guide Released

17 Mar

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Life Science Nation (LSN) has released the official Program Guide for RESI Europe 2026, taking place March 23 in Lisbon, Portugal, followed by four days of virtual partnering on March 24–25 and March 30–31.

The hybrid conference will bring together early-stage life science and healthcare innovators with a global network of investors and strategic partners actively sourcing opportunities across drugs, devices, diagnostics, and digital health.

A central highlight of the event is the Innovator’s Pitch Challenge (IPC), where more than 20 emerging companies will present their technologies directly to investor judges and the broader RESI partnering community. These presentations offer founders the opportunity to gain visibility, receive investor feedback, and initiate conversations that can lead to future funding and strategic collaborations.

The program also features investor panels, partnering meetings, and networking opportunities designed to help founders better understand the current investment landscape and build relationships with active investors and strategic partners.

With hundreds of one-on-one partnering meetings expected to take place across the hybrid format, RESI Europe provides a focused environment for early-stage companies to connect with capital and advance their fundraising and partnership strategies.

Registration is still open, and attendees can view the full conference program in the official Program Guide.

Register for RESI Europe

Tags: , , , , , , , , , , , ,

RESI Europe 2026 IPC Finalists 

10 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to announce the finalists for the Innovator’s Pitch Challenge (IPC) at RESI Europe 2026, taking place in Lisbon during the week of March 23. The event will bring together early-stage life science and healthcare innovators with a global community of investors seeking opportunities across drugs, devices, diagnostics, and digital health (4Ds).

This year’s IPC will feature over 20 presenting companies, with finalists pitching their technologies in dedicated sessions throughout the conference. These startups represent a diverse range of innovations aimed at solving critical healthcare challenges and advancing the next generation of life science breakthroughs.

The IPC gives founders the opportunity to pitch directly to active investors, including venture capital firms, family offices, corporate venture groups, and angel investors. Presenting companies receive valuable feedback from investor judges while gaining visibility among the investors and strategic partners attending RESI Europe.

Finalists will also have opportunities to connect with investors through RESI’s partnering system, as well as continue conversations during networking sessions and throughout the conference.

About the RESI Innovator’s Pitch Challenge

The IPC is a cornerstone of the RESI conference series. Each pitch session brings together a coordinated panel of investors who provide interactive feedback and questions designed to help founders refine their fundraising strategy and investment narrative.

Companies selected as IPC finalists receive RESI conference registration, the opportunity to present live to investors, and the chance to build relationships with members of the RESI investment community.

Join Us at RESI Europe 2026

RESI Europe 2026 will bring together founders, investors, and strategic partners for a full day of programming including investor panels, workshops from sponsors, networking opportunities, and the Innovator’s Pitch Challenge.

Attendees will have the opportunity to engage with the early-stage life science ecosystem through structured partnering meetings and educational sessions focused on fundraising and company development.

Register for RESI Europe

Meet the RESI Europe 2026 Innovator’s Pitch Challenge Finalists:

Applications Now Open for RESI San Diego

The Innovator’s Pitch Challenge at RESI San Diego offers life science startups the opportunity to present directly to a curated panel of active investors and receive real-time, constructive feedback. Each pitch includes a live Q&A with investor judges and extended exposure through participation in the IPC exhibition hall.

Apply to Pitch at RESI San Diego

 

Tags: , , , , , , , , , , , ,

Fundraising Bootcamp Ahead of RESI Europe 2026: Preparing Founders for Investor Engagement 

10 Mar

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation (LSN), in collaboration with Cuatrecasas, will host an exclusive Fundraising Bootcamp in Lisbon ahead of RESI Europe 2026, offering early-stage life science and healthcare executives a focused opportunity to refine their fundraising strategy and strengthen investor engagement skills. 

Taking place the day before the conference, the bootcamp will bring together founders, investors, and industry experts for an interactive session designed to help companies better position themselves for capital and partnerships within the global life science ecosystem. 

Event Details 

Date and Time: Sunday, March 22, 2026 | 2:00 PM – 5:30 PM
Location: Cuatrecasas Law Firm
Av. Fontes Pereira de Melo 6
1050-121 Lisboa, Portugal
Cost: Free to attend (registration required) 

This workshop will focus on practical, real-world fundraising insights that early-stage companies can immediately apply when engaging with investors at RESI Europe and beyond. Participants will hear directly from experienced professionals who work with startups and investors across the life science sector. 

Agenda Highlights 

Signal, Legibility, and Risk Mitigation in Global Fundraising 
Learn how investors interpret signals when evaluating early-stage companies and how founders can structure their development plans to become more “legible to capital.” The discussion will also explore strategies for mitigating risk in global fundraising environments. 

Shark Tank Session (Company Pitch) 
Selected companies will have the opportunity to present their pitch and receive direct feedback from experienced investors and industry professionals in an interactive format designed to sharpen messaging and highlight areas for improvement. 

Networking 
The bootcamp will conclude with time for founders and participants to connect with fellow entrepreneurs, investors, and industry experts before the start of RESI Europe. 

This pre-conference session provides a valuable opportunity for innovators preparing for RESI Europe to strengthen their fundraising approach, refine their investor messaging, and begin building connections within the RESI community. 

Space is limited, and applications will be accepted in the order they are received. 

Life Science Nation looks forward to welcoming founders and investors to Lisbon for this interactive fundraising session ahead of RESI Europe 2026. 

Sign up for Bootcamp

Tags: , , , , , , , , , ,

RESI San Diego 2026: Investor Panel Lineup Announced 

10 Mar

By Momo Yamamoto, Senior Investor Research Analyst, LSN

Life Science Nation (LSN) has announced the investor panel lineup for RESI San Diego 2026, taking place June 22 at the JULEP Venue in San Diego during Convention Week, followed by four days of virtual partnering on June 23–24 and June 29–30. The hybrid format combines in-person networking with extended virtual partnering, giving founders and investors additional opportunities to continue conversations and schedule meetings beyond the live event.

Investor panels are a cornerstone of the RESI conference series, bringing together active investors and strategic partners to share perspectives on the evolving life science funding environment. These sessions offer founders and executives the opportunity to hear directly from investors about how they evaluate opportunities across drugs, devices, diagnostics, and digital health.

This year’s discussions will explore several key themes shaping early-stage investment. Topics will include how emerging companies can successfully engage pharmaceutical partners, what strategic investors and corporate venture capital groups are prioritizing in today’s market, and how medtech innovators can position themselves to attract both financial and strategic partners. Panels will also examine investment trends in diagnostics and oncology, the growing role of artificial intelligence in healthcare innovation, and the challenges many startups face when moving from seed capital to institutional venture funding.

RESI San Diego 2026 Investor Panels

Time  Panel Title 
9AM  Inside Pharma Partnering 
How Early-Stage Companies Can Engage Pharma 
10AM  Strategic Partnerships in Medtech 
What the Next Generation of Device Companies Must Deliver 
11AM  Strategic Capital: The Role of CVCs 
Investing Where Innovation Meets Industry
1PM  New Frontiers in Diagnostics 
Investing in Technologies Enabling Earlier Disease Detection 
2PM  Emerging Approaches in Cancer Therapies 
How New Modalities Are Standing Out in a Competitive Market 
3PM  AI at the Frontlines of Healthcare Innovation 
Building Scalable Companies at the Intersection of Data and Medicine 
4PM  Crossing the Venture Gap 
Moving from Seed Funding to Venture Rounds 
Register for RESI San Diego
Apply to Speak at RESI San Diego

In addition to investor panels, RESI San Diego will feature the Innovator’s Pitch Challenge, where selected startups present their technologies directly to investor judges in an interactive pitch format. The conference also offers extensive one-on-one partnering opportunities, allowing attendees to schedule meetings with investors, strategic partners, and industry leaders through the RESI partnering system.

Held during San Diego’s broader biotech Convention Week, RESI San Diego provides a focused environment for early-stage companies to connect with active healthcare investors and strategic partners. The event brings together venture capital firms, family offices, corporate venture groups, and industry leaders seeking opportunities across drugs, devices, diagnostics, and digital health.

Register today to secure your place at RESI San Diego 2026 and connect with investors shaping the future of healthcare innovation. Super Early Bird rates are available through April 17.

Apply to Pitch at RESI San Diego

Tags: , , , , , , , , , , , , , , ,

Hot Investor Mandate: Investment Arm of Large Healthcare Enterprise Invests and Partners With Innovations With China and Global Market Potential

10 Mar

The firm is the investment arm of a diversified healthcare enterprise headquartered in Asia with international operations. The broader organization operates across medical innovation incubation, manufacturing, and large-scale commercialization, with a strong focus on technology-driven healthcare solutions and intellectual property development. Through its investment activities, the firm supports innovative healthcare companies by providing capital as well as access to industrial capabilities and commercialization infrastructure. The broader organization maintains a large healthcare distribution platform serving hospitals and pharmacies nationwide, enabling portfolio companies to access substantial market channels. The firm evaluates global investment opportunities with strong potential for commercialization in the China market.  

The firm focuses on life sciences and healthcare opportunities spanning therapeutics, diagnostics, medical devices, R&D tools, and AI-enabled healthcare platforms. Areas of particular interest include oncology and immuno-oncology, advanced therapeutic modalities such as cell and gene therapy, and innovative medical technologies with clear clinical application. Through its technology innovation initiatives, the organization collaborates with research institutions to identify and develop original scientific breakthroughs, including first-in-class medicines and novel medical devices. While the firm frequently evaluates later-stage assets and partnership opportunities, it also considers early-stage technologies with strong scientific differentiation and long-term commercial potential.  

From a company and partnership perspective, the firm prioritizes opportunities with meaningful relevance to the China healthcare market and the ability to leverage the organization’s regulatory, manufacturing, and commercial infrastructure. The firm looks for strong scientific foundations, clear unmet clinical needs, differentiated product positioning, and credible strategies for market entry and expansion. Portfolio companies may benefit from support across R&D collaboration, industrial incubation, regulatory strategy, manufacturing scale-up, and nationwide commercialization. The firm maintains a flexible investment approach and may participate as either a lead investor or a co-investor depending on the opportunity and partnership structure. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

← Older Entries
Newer Entries →